Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET) by Bahri, Priya et al.
                                                                    
University of Dundee
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation
from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the
Novel Analysing Stakeholder Safety Engagement Tool (ASSET)
Bahri, Priya; Morales, Daniel R.; Inoubli, Adrien; Dogné, Jean-Michel; Straus, Sabine M. J. M.
Published in:
Drug Safety
DOI:
10.1007/s40264-020-01005-3
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Bahri, P., Morales, D. R., Inoubli, A., Dogné, J-M., & Straus, S. M. J. M. (2020). Proposals for Engaging Patients
and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate
Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Safety.
https://doi.org/10.1007/s40264-020-01005-3
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. Nov. 2020
Vol.:(0123456789)
Drug Safety 
https://doi.org/10.1007/s40264-020-01005-3
ORIGINAL RESEARCH ARTICLE
Proposals for Engaging Patients and Healthcare Professionals 
in Risk Minimisation from an Analysis of Stakeholder Input to the EU 
Valproate Assessment Using the Novel Analysing Stakeholder Safety 
Engagement Tool (ASSET)
Priya Bahri1 · Daniel R. Morales2,6 · Adrien Inoubli3,6 · Jean‑Michel Dogné4,6 · Sabine M. J. M. Straus5,6
Accepted: 16 September 2020 
© The Author(s) 2020
Abstract
Introduction Understanding the impact of regulatory actions for medicines and enablers/barriers for positive health outcomes 
is fundamental to effective risk minimisation measures (RMM). Therefore, the Impact Strategy of the European Union (EU) 
Pharmacovigilance Risk Assessment Committee (PRAC) includes engagement with patient communities and healthcare 
professional (HCP) bodies regarding RMM. However, there is uncertainty on how best to obtain stakeholder input.
Objectives The objectives of this study were to (1) analyse stakeholder input at a public hearing and dedicated meeting for 
the 2017–18 EU procedure on valproate teratogenicity and (2) draw proposals for enhancing PRAC engagement.
Methods For the content analysis, the novel ‘Analysing Stakeholder Safety Engagement Tool’ (ASSET) was developed with 21 
themes in six domains (appropriateness, access, audience, compatibility, integrability, time), based on implementation theories.
Results Stakeholders provided a wide range of RMM proposals, some beyond the regulatory remit. Patients and most HCPs 
converged remarkably, but there was some divergence among HCPs on the informed choice objective, the therapeutic place 
of valproate, the RMM appropriateness, and RMM delivery to HCPs and patients. Ethical aspects emerged as relevant for 
regulatory decision making, and crucial input gaps were identified from an RMM implementation perspective. Nine pilotable 
proposals for PRAC were made regarding: (A) Agreeing on appropriate RMM with stakeholders and catalysing healthcare 
leadership for implementation; (B) Building-up stakeholder input on all elements critical to RMM implementation guided 
by the ASSET; and (C) Collaborating with all stakeholders for monitoring implementation and evaluating RMM.
Conclusions New implementation theory-based approaches are promising for enhancing the valuable dialogue between 
regulators, patients and HCPs and achieving patient safety.
EU PAS Register number: EUPAS35947
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Key Points 
European Union regulators highly value the input 
received from patients and healthcare professionals at 
their first ever public hearing and dedicated stakeholder 
meeting on valproate birth defects; however, they have 
identified crucial gaps in input and research into risk 
minimisation effectiveness by using a new approach 
presented here based on implementation science.
Derived proposals for regulators to remedy these gaps 
aim at catalysing stakeholder agreement and healthcare 
leadership for the implementation of risk minimisation 
measures, building up more comprehensive stakeholder 
input, and collaborating with all stakeholders for moni-
toring implementation and evaluative research.
Pilotable and practicable actions are presented to 
enhance the dialogue between regulators, patients, and 
healthcare professionals and to lead to risk minimisation 
measures that are implementable in real-world healthcare 
for patient safety.
1 Introduction
1.1  Objective of Pharmacovigilance
Pharmacovigilance comprises the science and activities 
relating to the detection, assessment, understanding, and 
prevention of adverse effects of medicines or any other med-
icine-related problem [1]. Legal pharmacovigilance obliga-
tions apply to regulatory bodies and marketing authorisa-
tion holders (MAHs). Measuring the impact of regulatory 
decisions as well as identifying enablers and barriers for 
effective risk management are fundamental for the success 
of regulatory medicinal product-specific risk minimisation 
measures (RMM). Such RMM are imposed on MAHs, and 
patients and healthcare professionals (HCPs) are central 
stakeholders. Effectiveness evaluations of RMM may trig-
ger adjusted or new RMM and thus serve pharmacovigi-
lance quality management [2]. However, the effects of RMM 
are often poorly quantified because of limitations in data 
sources and the choice of methods used for evaluation [3–6]. 
Considering RMM as planned health interventions calls for 
formative research [7] into likely RMM effectiveness before 
regulatory decision making, to find the most adequate RMM. 
The established product management cycle for ensuring 
that the benefit-risk balance remains positive can hence be 
expanded with implementation of RMM in healthcare as 
part of the cycle, formative research into RMM options and 
implementability, and feedback from patients and HCPs on 
experiences with using the medicine and RMM in healthcare 
for the evaluation step (Fig. 1).
1.2  European Union Initiative 
for Pharmacovigilance Impact
In the European Union (EU), routine RMM include the 
authorised product information, and additional RMM may 
be imposed as needed, such as controlled access, educational 
materials or pregnancy prevention programmes (PPPs). 
Monitoring their effectiveness is a legal requirement for 
MAHs in the context of risk management plans [8]. Con-
sidering options for RMM and monitoring outcomes of 
regulatory actions are within the legal mandate of the EU 
regulatory network [9, 10]. The Pharmacovigilance Risk 
Assessment Committee (PRAC) at the European Medicines 
Agency (EMA) therefore has a ‘Strategy for Measuring the 
Impact of Pharmacovigilance Activities’ [11], which aims 
at further developing proactive pharmacovigilance, includ-
ing through active engagement and capacity building with 
patient communities and HCP bodies [12, 13].
1.3  Mechanisms of Pharmacovigilance Risk 
Assessment Committee Engagement 
with Patients and Healthcare Professionals
Within the existing EMA stakeholder engagement frame-
work [14], the risk assessment process of PRAC contains 
various options for interacting with patients and HCPs. 
These consist of written consultations (targeted to organi-
sations and individuals of the EMA’s stakeholder network) 
and meetings, i.e. dedicated meetings (with invited par-
ticipants from the EMA’s stakeholder network and expert 
pool), scientific advisory group  (SAG) meetings (with 
invited HCPs, academics and patients from the EMA’s 
expert pool) and public hearings (open to all EU citizens 
and organisations, including MAHs, as well as parties out-
side the EU). Since PRAC was established in 2012, all these 
engagement mechanisms have been used. The public hear-
ing [15] is the most recently added tool to obtain input from 
a wide range of stakeholders.
1.4  Current Uncertainties Regarding Engagement
However, uncertainty remains about the optimal approach 
for engaging with patients and HCPs. Public hearings held 
by the US Food and Drug Administration have shown that 
contributions from patients and HCPs may be qualitatively 
different from what the data regulators usually review, and 
some argue that regulators need a specific process for solic-
iting and integrating the views from patients and HCPs for 
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regulatory decision making [16]. International multi-stake-
holder experts have also recognised the need for optimising 
this integration for strengthening benefit-risk assessment, 
communication/risk minimisation and evaluation (BRACE) 
[17].
2  Objectives and Methods
The aim of this study was to further develop active engage-
ment and capacity building with patient communities and 
HCP bodies regarding effective risk minimisation through 
the use of a case study with the following objectives:
1 Analyse the input from patient and HCP representatives 
regarding RMM during a public hearing and dedicated 
meeting as major face-to-face interactions, including 
comparisons between these two engagement mecha-
nisms and between the two stakeholder groups; and
2 Draw, based on the findings of (1), proposals to be con-
sidered by PRAC for enhancing their engagement pro-
cess with patients and HCPs for effective risk minimisa-
tion.
The following methods were applied:
2.1  Case Study on the 2017–18 European Union 
Procedure on the Teratogenic Risk of Valproate
A public hearing was used for the first time by PRAC and 
followed by a dedicated meeting when assessing the terato-
genic risk of valproate in 2017–18. Valproate is an active 
substance used for treating epilepsy and bipolar disorders as 
well as, in some EU member states, for preventing migraine 
headaches. However, it may be teratogenic when taken 
during pregnancy and cause malformations and lifelong 
Fig. 1  Life cycle management of medicinal products for improv-
ing the benefit-risk balance developed from [17] and expanded with 
implementation of risk minimisation in healthcare, formative research 
into risk minimisation options and implementability, and feedback 
from patients and healthcare professionals on using the medicine and 
risk minimisation in healthcare for evaluation
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neurodevelopmental harm in the child. The evidence for 
these effects has been accumulating over time and been 
subject to assessments at the EU level in 2002–04, 2014 
and 2017–18 (see [18, 19] for the references to the evidence 
assessed by PRAC, i.e. the new committee established in 
2012) (see Table 1).
2.2  Recording Input from Patient and Healthcare 
Professional Representatives
Stakeholder input to PRAC is provided within public hear-
ings as written submissions and in speech (published as sub-
mitted/video recording on the EMA website). Input within 
dedicated meetings is provided in speech only (reflected in 
the public PRAC assessment reports on the EMA website). 
For their decision-making, PRAC uses the written submis-
sions and, for speech input, summaries of responses and 
discussions prepared by EMA. The case study used the writ-
ten submissions and the video recording as the records to 
be analysed for the public hearing and verbatim transcripts 
(specifically made for the study as exhaustive as possible in 
handwriting or typing by EMA staff members) of the speech 
input as records to be analysed for the dedicated meeting.
2.3  Developing a Content Analysis Tool Based 
on Implementation Theories
For analysing the input from patients and HCPs, a content 
analysis tool was developed prior to the public hearing and 
dedicated meeting, and independent from the sets of PRAC 
questions used at the hearing/meeting (for the PRAC 
questions, see Appendix 1 of the ESM). Content analy-
ses are qualitative research and can be used to describe 
phenomena not yet well understood and to be explored 
Table 1  Pharmacovigilance Risk Assessment Committee (PRAC) assessments of the teratogenic risk of valproate
EU European Union, HCP healthcare professional, MAHs marketing authorisation holders, PPP pregnancy prevention programme, RMM risk 
minimisation measure(s), SAG scientific advisory group
EU procedure Assessment outcome
EU referral review by PRAC in 2014 PRAC agreed to strengthen restrictions for the use of valproate in female patients who are pregnant 
or can become pregnant, to advise on effective contraception in female individuals for whom 
valproate is the only option after trying other treatments, and to require prescribing physicians 
to fully inform female patients about the teratogenic risk and regularly review their treatment. 
PRAC agreed to update the authorised product information accordingly and to require provision 
of educational materials (e.g. patient information booklet, checklist for prescribers, checklist for 
patients, information acknowledgement form) to all HCPs and female patients prescribed val-
proate in the EU. A dedicated meeting with concerned women and a SAG meeting with experts 
in neurology, psychiatry, obstetrics and paediatrics, and patient representatives had been part of 
this EU procedure prior to decision making on the actions [20]. The option of the public hearing 
had not yet been implemented and available to PRAC in 2014.
EU referral review by PRAC in 2017–18 In March 2017, a new EU procedure was initiated by PRAC to review the effectiveness of the 
RMM introduced in 2014 and the potential need for further RMM, triggered by concerns and 
data that the 2014 RMM were not as effective as intended. During this procedure, PRAC used all 
available options for involving patients and HCPs, i.e. a written consultation launched in March 
2017, a public hearing on 26 September, 2017, SAG meetings, and a dedicated meeting with 
patients and HCPs on 13 October, 2017.
In the written consultation, the questions posed by PRAC to patients and HCP representatives 
related to receipt of information, utility of the educational materials, risk awareness, prescrib-
ing, other relevant healthcare behaviours and the implementation of the 2014 RMM overall. 
The responses consisted of real-world feedback and data, including from surveys that targeted 
patients and HCP organisations had conducted among their members. At the same time, informa-
tion was collected by EMA from the regulatory authorities in EU member states. Almost all 
member states confirmed the dissemination of materials to healthcare settings, but data on the 
effectiveness of the RMM were limited. The MAHs for valproate-containing medicinal products 
were obliged to provide all data on RMM effectiveness available to them, and these included data 
across several member states from healthcare research organisations. The information collected 
from all stakeholders at the early stage of the procedure indicated that the effectiveness of the 
2014 RMM might have been impaired by their delayed, incomplete or inadequate implementa-
tion in healthcare.
Taking into account all evidence and further stakeholder input during the public hearing and 
dedicated meeting (for the PRAC questions, see Appendix 1 of the Electronic Supplementary 
Material [ESM]; for the list of speakers, video recording and written submissions for the public 
hearing, see [21]), PRAC agreed further product information updates and RMM, i.e. restrictions 
of use in female patients and a comprehensive PPP, which includes individualised care, commu-
nication and disease management. This procedure was concluded on 31 May, 2018 [21].
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by organising and unifying content items by themes [22, 
23]. Such studies apply an interpretative approach to con-
tent and are concerned with understanding the meanings 
that persons attach to actions, decisions, beliefs and values 
as well as with understanding the mental processes persons 
use to make sense of the world around them [24]. Qualita-
tive research is still rare in regulatory pharmacovigilance 
contexts but has previously been undertaken within the 
EU regulatory network when conducting media monitor-
ing and has proven utility for preparing for vaccine safety 
communication with journalists, members of parliaments 
and the public [25].
For this case study, the themes were developed with a 
deductive approach based on existing implementation the-
ories (see Table 2). Implementation science is the study 
of methods to promote the adoption and integration of 
evidence-based practices, interventions and policies into 
routine healthcare and public health settings [26] as com-
plex systems [27]. This includes studying why implemen-
tation succeeds or fails [28]. Implementation hence cov-
ers all processes from disseminating knowledge and skills 
to practicing medical care for positive patient and public 
health outcomes. Implementation theories were chosen as 
the basis for the content analysis tool because the 2017–18 
EU procedure was triggered by concerns that the 2014 
RMM were not sufficiently effective and the study therefore 
assumed that strengthened RMM implementability would 
be a target outcome of the procedure. It was also considered 
that implementation is key to RMM effectiveness for any 
product and that this approach might be generalisable for 
future application.
The content analysis tool was finalised with 21 themes 
in six domains, providing for structure and granularity of 
the analysis and taking into account that different actors 
may be responsible for different steps of implementation 
(for details on the development of the content analysis tool, 
see Appendix 2 of the ESM). The tool was named the ‘Ana-
lysing Stakeholder Safety Engagement Tool’ (ASSET) (see 
Table 3).
2.4  Analysing Input from Patient and Healthcare 
Professional Representatives
2.4.1  Inclusion of Input
Only RMM-related content of the recorded input was ana-
lysed. Given the scope of implementation covering all pro-
cesses from disseminating knowledge and skills to practicing 
medical care [26], any input from patient and HCP repre-
sentatives relating to regulatory or healthcare action that 
may help to reduce harm was considered RMM-related con-
tent, which went beyond the regulatory meaning of RMM.
Table 2  Implementation theories underpinning the content analysis tool
HCP healthcare professional, KAP knowledge, attitudes, practices, RMM risk minimisation measure(s), SMART specific, measurable, appropri-
ate and agreed, realistic, and time-bound
Implementation theories
SMART criteria for strategic health communication
Purpose: Objective setting for health communication interventions within a model of stakeholder participation
Objective: Reach defined audiences with tailored multi-media approaches and help them to adopt healthy behaviours [29]
Theory: 5 criteria for strategic objectives have been coined ‘SMART’: (1) specific in terms of the behaviour called for; (2) measurable for the 
purpose of evaluation; (3) appropriate for remedying the problem and agreed amongst stakeholders; (4) realistic, taking into account the 
present systems and potential for change; (5) time-bound, i.e. having a set point in time by which the action should and can be implemented 
[29, 30]. These criteria have already been adapted for a strategic approach to communication about the risks and safe use of medicines [31] and 
here have an additional emphasis on the appropriateness of the action for remedying safe use issues
KAP model for evaluating learning
Purpose: Improving learning interventions in complex environments
Objective: Evaluate changes in KAP, i.e. knowledge, attitude and practice, and help learners to adopt new behaviours for better performance [32]
Theory: Knowledge instruction alone is insufficient to influence behaviour, and knowledge, attitude and behaviour are interconnected. The 
attitude component acknowledges the crucial role of beliefs, values, emotions and motivation in learning and behaviour change [32]. The KAP 
model has been applied in the area of health [33, 34], and implementation science refers to this model [27]
Implementation science-based pharmaceutical risk management
Purpose: Advancing risk management of medicines using implementation theories and communication strategies with patient- and stakeholder-
centredness
Objective: Deliver RMM to HCPs and patients and help them to adopt safe medicine use behaviours
Theory: 3 features for optimal RMM implementation: (1) organisation and delivery; (2) process measures; and (3) sustainability. Recommenda-
tions relate to: for (1): collaboration and governance, readiness to change, championship, training and assistance; for (2): reach, adoption by 
healthcare facilities, fidelity to RMM design, available resources/acceptable burden; for (3): sharing of promising practices, continuing of 
training and assistance. Underpinning principles are: adaptable, multi-faceted, multi-level, using socio-ecological models, aiming at healthcare 
workflow compatibility [35]
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2.4.2  Exclusion of Input
Content not relating to RMM was not analysed, nor the input 
from the MAH speaker at the public hearing. Body language 
was also not part of the analysis (body language includes 
posture, movement, gestures, facial expression, eye contact, 
and tone of voice [36] and may hence add content or express 
agreement or disagreement with statements of others).
2.4.3  Content Analysis of Included Input
The content was summarised and organised into a tabulated 
format of the ASSET. Regulatory terminology was applied 
consistently in these summaries, but some verbatim quotes 
were included for illustration (e.g. ‘contraindication’ as the 
regulatory term and in addition “ban” [in certain clinical 
circumstances] as a quote). This terminological consistency 
facilitated the comparisons between stakeholder groups and 
engagement mechanisms. Additionally, it was analysed as 
to which implementation-relevant aspects were provided 
in response to which question, to gain insight into how far 
PRAC questions provided for focus (e.g. if all representa-
tives provided input categorised into a certain ASSET 
theme in response to only one question, the question would 
be considered specific and focused from an implementation 
perspective).
The analysis was not conducted quantitatively in terms 
of how much discussion time was taken for each aspect, or 
how often certain content was repeated, or how many repre-
sentatives provided similar content or agreed explicitly with 
Table 3  Analysing Stakeholder Safety Engagement Tool (ASSET)
HC healthcare, HCP healthcare professional, KAP knowledge, attitudes, practices, RMM risk minimisation measure(s)
Domain Theme Theme code
1 Appropriateness of RMM for harm reduction 1.1 Type of RMM components and their specific 
capacity for harm reduction when fully imple-
mented
Specific capacity
1.2 Ethical considerations regarding RMM Ethics
1.3 Agreement within HCP communities responsible 
for patient care that RMM is appropriate
HCP agreement
2 Access-to-treatment-related acceptability of 
RMM
2.1 Deprivation of the medicine and its benefits Benefit deprivation
2.2 Impact of RMM on patient adherence to medica-
tion
Adherence to medicine
2.3 Benefit-risk balance of alternative treatments to 
which RMM might channel
Alternative benefit-risk balance
3 Audience-tailored approach to RMM 3.1 Current knowledge, attitude and practice of HCPs Prior HCP KAP
3.2 Current knowledge, attitude and practice of 
patients/parents/carers
Prior patient KAP
3.3 Information and training needs and interests of 
HCPs
HCP needs
3.4 Information, training and counselling needs and 
interests of patients/parents/carers
Patients needs
3.5 Preferences for tools informing HCPs HCP tool preference
3.6 Preferences for tools informing patients/parents/
carers
Patient tool preference
4 Compatibility of RMM with healthcare structures 
and resources
4.1 Compatibility of RMM with the structures of the 
healthcare system
HC compatibility
4.2 Compatibility of RMM with clinical guidelines Guideline compatibility
4.3 Burden of RMM for the patient Patient burden
4.4 Compatibility of RMM with healthcare reim-
bursement policy
Reimbursement compatibility
5 Integrability of RMM in healthcare processes 5.1 Responsible delivery of RMM to HCPs Responsible delivery to HCP
5.2 Responsible delivery of RMM to patients Responsible delivery to patient
5.3 Measurability of RMM implementation and 
evaluation for improvement action
Measurability
6 Time-bound requirements of RMM 6.1 Immediate RMM implementation in healthcare Immediate effect
6.2 Sustainability of RMM implementation in health-
care
Sustainable effect
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a statement made. This methodological choice was made to 
treat each statement made by a stakeholder as equally impor-
tant to be heard and considered for the decision making on 
RMM, keeping it with the qualitative research approach.
2.4.4  Identification of Input Gaps
As part of the content analysis, ASSET themes for which 
only limited stakeholder input had been obtained or the dis-
cussion did not lead to agreement on RMM and convergence 
on solutions for overcoming potential barriers to RMM 
implementation were identified as input gaps.
3  Results
3.1  Content Analysis of the Patient and Healthcare 
Professional Input for the 2017–18 European 
Union Procedure on Valproate Teratogenicity
The content analysis yielded the following key findings (for 
details on the analysis, see Table 4 and Appendix 3 of the 
ESM).
3.1.1  Input by Themes and Input Gaps
• The input covered all themes relevant to RMM imple-
mentation, albeit to a variable extent. Stakeholders 
detailed severe shortcomings in the implementation of 
the 2014 RMM with evidence.
• A wide range of future RMM was proposed, but without 
presenting much evidence gained for valproate or other 
medicinal products from previous RMM experiences and 
evaluations on the capacity to reduce harm when fully 
implemented. Overall, the favoured RMM objectives 
were: to limit exposure to valproate in epileptic women 
of childbearing potential; to reduce risks of birth defects 
due to valproate exposure in utero; and to facilitate an 
informed choice for women regarding pregnancy. Many 
RMM proposals went beyond the regulation of medicines 
and related to healthcare (theme 1.1). Ethical questions 
relevant to applying RMM in healthcare were also raised 
(theme 1.2).
• A clear call was made to not deprive patients from the 
benefits of valproate where needed (theme 2.1) and to not 
jeopardise patient adherence to treatment in these cases 
(theme 2.2).
• A number of specific needs for tailoring RMM for 
patients and HCPs were highlighted to overcome cur-
rent shortcomings in knowledge, attitudes and practices 
(themes 3.1 and 3.2) and address patients’ expectations 
for information and counselling (themes 3.4 and 3.6) and 
increase HCP skills to communicate with patients and 
deliver RMM (themes 3.3 and 3.5). Input gaps were left 
regarding who should develop and provide HCP training 
on risk management and communication skills (theme 
3.3); which information items precisely should be con-
veyed to patients and how to frame them (theme 3.4); 
and who should provide leadership for developing and 
disseminating tailored RMM to various HCP types via 
all available channels (theme 3.5).
• Burden for patients associated with RMM, resource con-
straints and contraception reimbursement policies were 
discussed as barriers to implementing RMM. However, 
the discussion did not try to outline RMM that could be 
bearable for patients (theme 4.3), or how RMM would be 
compatible with the existing healthcare structures (theme 
4.1) and reimbursement policies (theme 4.4). The need 
for incorporating RMM into clinical guidelines was high-
lighted, and some, but not all, HCPs voiced commitment 
for advocating RMM within their respective professional 
communities (theme 4.2).
• There was some, but no resolving discussion on how pro-
posed RMM could actually be best delivered to HCPs 
(theme 5.1) and be integrated into healthcare processes, 
and who will be responsible for healthcare leadership 
to ensure behavioural change for the benefit of patients. 
Only the patient card was discussed in the context of 
the dispensing process (theme 5.2). Patient and HCP 
representatives called for RMM to be driven by clear 
objectives and followed up through auditing and effec-
tiveness measurement. They provided good suggestions 
for evaluative methods, but some uncertainty remained 
about how to improve survey methods. A responsible 
actor for the proposed healthcare audits was not identi-
fied (theme 5.3).
• Timebound requirements were highlighted with a view to 
an urgent outreach to patients for immediate effectiveness 
(theme 6.1) as well as to sustainability of RMM effective-
ness over time (theme 6.2), but without defining actors 
and processes to achieve these goals.
3.1.2  Input by Stakeholder Groups
• Between patient and HCP representatives, there was a 
remarkable convergence in views and favoured RMM 
objectives overall.
• Divergence occurred among HCP representatives in rela-
tion to capacity of some RMM for harm reduction (theme 
1.1); the informed choice objective questioned by one 
HCP representative (theme 1.2); the therapeutic place of 
valproate and the underlying evidence (theme 2.1); and 
the delivery of RMM to HCPs (theme 5.2) [see theme 1.3 
focussing on agreement of HCP representatives overall].
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Table 4  Summary results of the content analysis using the Analys-
ing Stakeholder Safety Engagement Tool (ASSET) with identifica-
tion of gaps of the patient and healthcare professional (HCP) input to 
the public hearing on 26 September, 2017 (PH) and dedicated stake-
holder meeting on 13 October, 2017 (DM) for the 2017/18 European 
Union procedure on valproate teratogenicity
Domain Theme code Summary content analysis results and input gaps
1 Appropri-ateness 
of RMM for harm 
reduction
1.1 Specific capacity At PH, there were statements that 2014 RMM contained appropriate information, 
but that there was a lack of dissemination and further implementation steps, 
and also statements on insufficiency of 2014 RMM. 23 tool proposals for RMM 
strengthening were made: restriction of indication; limitation of exposure in 
women of childbearing potential; limitation of exposure in pregnancy; patient 
reviews/counselling/pregnancy planning provided by physician; contraception; 
dosing; plasma level monitoring during pregnancy; co-medication during preg-
nancy; qualified prescriber; prescribing checklists; prescription validity time; 
dispensing process; dispensing software alarms; product information warning; 
pictogram; patient information card; information receipt form; pharmacy checks 
of patient’s information receipt; risk information provision at family planning 
counselling; financial incentives for HCPs; risk information and awareness 
campaigns; clinical guidelines; data collection. At DM, 22 proposals or support 
to PRAC proposals (incl. calls for a PPP) were made: restriction of indication; 
limitation of exposure in women of childbearing potential/fertile men; limita-
tion of exposure in pregnancy; patient reviews/counselling/pregnancy planning 
provided by physician; contraception; dosing; plasma level monitoring during 
pregnancy; co-medication during pregnancy; specialist care; controlled access 
programme; qualified prescriber; named patient prescription; restriction of 
prescription volume; coded prescribing; pack size harmonisation; product infor-
mation warning; pictogram; patient information card; information receipt form; 
risk information and awareness campaigns; RMM implementation for Internet 
sale; data collection. RMM proposals were similar at PH and DM, but some 
PH proposals were not followed up at DM, where a few other proposals were 
discussed (marked in italics), some of which triggered by the PRAC questions. 
At DM, additional RMM needs owing to concerns over exposure through semen 
were raised. There was overall convergence between PTR and HCPR, but among 
HCPR, there was divergence regarding specialist prescribing, dose monitoring 
and adjustment during pregnancy, folic acid co-medication and the informa-
tion receipt form. PTR made a call for “more collaborative action across EU”. 
Proposals for RMM tools were provided in response to all PRAC questions
Input gaps: Evidence gained from previous RMM experiences and evaluations 
and convergence on if and/or how specific proposed RMM have the capacity to 
reduce risks and/or improve health outcomes, provided full implementation can 
be achieved
1.2 Ethics Aspects of ethical dimension and related dilemmas for HCPs were discussed 
and specific questions raised that centred on the complex situation of maternal 
need for treatment, the adverse effects for the child exposed in-utero and the 
mother caring for the child, and the risks of under-/untreated epilepsy for the 
woman and the unborn child. Overall, there was convergence at PH and DM and 
between PTR and HCPR for an informed choice of women, with divergence 
of one HCPR. The ethical dimension of the RMM decision was reflected in the 
responses to most PRAC questions
Input gaps: Full convergence on RMM objectives in ethically challenging situa-
tions
1.3 HCP agreement At PH and DM, lack of full HCPR agreement with proposed RMM manifested 
in divergence among HCPR arising from differences in views on the specific 
capacity of some RMM to reduce harm (see 1.1), the therapeutic place of 
valproate and the underlying evidence (see 2.1), the informed choice objective 
(see 1.2) and the delivery of RMM to HCPs (see 5.2). There was explicit sup-
port from some/across HCPR for RMM proposals such as product information 
and the patient card. The views were voiced in response to a range of PRAC 
questions
Input gaps: Agreement of HCPR on most appropriate RMM to reduce harm (see 
1.1), the therapeutic place of valproate (see 2.1), the informed choice objective 
(see 1.2) and the responsible delivery of RMM to HCPs (see 5.2)
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Table 4  (continued)
Domain Theme code Summary content analysis results and input gaps
2 Access-to-treatment-
related acceptabil-
ity of RMM
2.1 Benefit deprivation This theme was discussed more at PH than DM, mainly by HCPR, and revealed 
divergence regarding the therapeutic place of valproate and the underlying 
evidence. There was however convergence among HCPR and PTR that the val-
proate treatment option needs to be preserved and RMM should not to deprive 
women in need of valproate benefit
Input gaps: Convergence of HCPR on the therapeutic place of valproate
2.2 Adherence to medicine There was convergence between PTR and HCPR at PH and DM that inconsistent 
or inadequate risk information from healthcare or social channels can lead to 
patient non-adherence to treatment
2.3 Alternative BR There were similar concerns voiced by HCPR at DM and PH over risks of alterna-
tive medication, albeit at PH there also was a statement on the potentially better 
benefit-driven BR of alternative medication, which also related to the diver-
gence regarding the therapeutic place of valproate (see 2.1). At DM, this input 
was provided in relation to PRAC questions on the mandatory checklist and bar-
riers to switching
3 Audience-tailored 
approach to RMM
3.1 Prior HCP KAP This theme was discussed more at PH than DM in line with the respective PRAC 
questions. The discussion showed convergence between PTR and HCPR that 
current HCP knowledge, attitude and practices, incl. risk communication skills, 
are not in accordance with 2014 RMM implementation, and there were also 
HCPR statements that RMM implementation does not happen in healthcare. 
This was supported by evidence from patient organisation surveys. Input rel-
evant to this theme arose from responses to multiple PRAC questions
3.2 Prior patient KAP This theme was discussed more at PH than DM in line with the respective PRAC 
questions, and the discussion showed convergence between PTR and HCPR 
with the evidence of patient organisation surveys and published literature find-
ings that current risk knowledge in women is insufficient and that patients with 
knowledge have an attitude to avoid valproate. The DM discussion added patient 
non-adherence to epilepsy treatment in general as an issue. Input relevant to this 
theme arose from responses to multiple PRAC questions
3.3 HCP needs There were similar information needs, mainly on the management of risks and 
adverse effects, identified at PH and DM by PTR and HCPR as well as a training 
need for communication skills to provide risk information and counselling to 
female patients. Input relevant to this theme arose from responses to multiple 
PRAC questions
Input gaps: Actors and leadership for developing and providing HCP training for 
risk management and communication skills
3.4 Patient needs There were similar risk information and counselling needs, incl. on the potential 
life impact of teratogenic effects, pregnancy planning, contraception and alterna-
tive parenting, identified at PH and DM by PTR and HCPR, alongside how such 
information needs to be presented. However, there was one HCPR statement 
also informing about the possibility of having a healthy child with valproate, 
which was opposed by PTR and hence constitutes divergence in the informa-
tion women should be informed about and how this should be framed. Aspects 
relevant to this theme were raised in response to almost all PRAC questions
Input gaps: List of risks and other information items for patients, their presenta-
tion and framing
3.5 HCP tool There was similar input at PH and DM, more during PH though, in response to 
multiple PRAC questions and mainly from HCPR themselves, providing prefer-
ences and proposals for a range of user-tested print, electronic and conference-
based tools for providing RMM information to HCPs. One HCPR committed to 
dissemination via the scientific journal of his professional organisation
Input gaps: Actors and leadership for developing and providing dissemination 
tools for HCPs, incl. proposals from HCPR to use all their available channels
3.6 Patient tool There was similar input at PH and DM in response to multiple PRAC ques-
tions, mainly from PTR themselves on preferences and proposals for multiple 
user-tested tools for providing RMM information to patients, with a visual risk 
presentation in the form of a pictogram being a major preference
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Table 4  (continued)
Domain Theme code Summary content analysis results and input gaps
4 Compat-ibility of 
RMM with health-
care structures and 
resources
4.1 Healthcare compatibility There was similar input at PH and DM from PTR and HCPR in response to almost 
all PRAC questions, highlighting that lack of resources, coordination across 
healthcare and insufficient availability of specialist care in at least some MS con-
stitute major barriers to RMM implementation
Input gaps: Proposals for RMM that are compatible with existing healthcare 
structures and resource constraints, or proposals on how to free/make needed 
resources available in the overall care of the given patient population 
4.2 Guideline compatibility At PH and DM, in response to the PRAC question regarding the GP role, PTR and 
HCPR considered RMM implementation in clinical guidelines important
Input gaps: Leadership and commitment for transposition of RMM in clinical 
guidelines
4.3 Patient burden HCPR at DM, in response to PRAC questions on signed consent forms and 
pregnancy prevention plans, voiced concerns over patient burden associated 
with monthly pregnancy testing or with the annual information receipt forms by 
women without childbearing potential as barriers to RMM implementation
Input gaps: Proposals for making RMM bearable to patients
4.4 Reimbursement compat-
ibility
At DM, PTR and HCPR identified, in response to PRAC questions on pregnancy 
prevention plans and obstacles to switching, the absence of reimbursement 
schemes for contraception as a barrier to RMM implementation
Input gaps: Proposals for RMM compatible with the existing reimbursement poli-
cies or proposals for making needed resources available
5 Integra-bility of 
RMM in health-
care processes
5.1 Responsible delivery to 
HCP
This was discussed in a similar manner at PH and DM, but more at PH, with a call 
to strengthen or mandate RMM delivery to HCPs and divergence in views on 
who is the responsible organisation for RMM delivery, i.e. only public bodies 
or MAHs too. Some PTR and some HCPR accepted MAHs as responsible for 
delivery of RMM information, while some HCPR preferred regulatory bodies as 
senders and/or voiced concerns over undue marketing by MAHs, and some PTR 
preferred independent advisors to HCPs
Input gaps: Planning of delivery of RMM to HCPs in accordance with roles 
and responsibilities of MAHs, regulatory bodies, and other stakeholders and 
methods to convey the mandatory nature of RMM to HCPs incl. how to ensure 
dissemination, information adoption and leadership for behavioural change of 
HCPs required for RMM implementation
5.2 Responsible delivery to 
patient
There was a strong call from PTR and HCPR at DM and PH for the delivery of 
RMM to patients in a responsible and coordinated manner by the healthcare 
system in the framework of annual reviews and counselling. However, there was 
divergence among HCPR regarding who can take the responsibility of informa-
tion delivery to patients, i.e. GPs and/or specialists, or pharmacists instead 
of GPs, or nurses. This theme was discussed in response to almost all PRAC 
questions
Input gaps: Planning of delivery of RMM to patients in accordance with roles and 
responsibilities of MAHs and regulatory bodies, and integration of RMM tools 
into healthcare processes with agreement among HCPs and leadership on col-
laborative roles and responsibilities of HCP types
5.3 Measurability This was discussed at PH and DM with similar calls from HCPR and PTR for 
RMM that are outcome-driven and evaluated. More detailed methodological 
proposals were provided at DM in response to a specific PRAC question, albeit 
the theme also emerged in response to two other questions. Quantitative meth-
ods, e.g. surveys and health record/prescription data analysis, and qualitative 
methods as well as RMM implementation in clinical guidelines and compli-
ance audits were proposed by PTR and HCPR. Some divergence consisted in 
one HCPR questioning the validity of surveys because of potential recall bias, 
specifically in the given patient population
Input gaps: Improvements to survey methodology and identification of a responsi-
ble actor for healthcare audits
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3.1.3  Input in Relation to the Pharmacovigilance Risk 
Assessment Committee Questions
• In each EU procedure, questions posed by PRAC to 
stakeholders are specific to the given medicinal prod-
uct and safety concern, but at the same time are kept 
broad to allow stakeholders to elaborate on aspects that 
may be new to regulators. In the case of valproate, the 
input did not always match the question asked at the 
given moment, and most themes were brought up multi-
ple times in response to different questions. This was to 
be expected during the public hearing where the PRAC 
questions were high level and posed with the option for 
stakeholders to address them in an integrated response. 
The partial disconnect between questions and answers 
was more unexpected during the dedicated meeting, 
where the PRAC questions were more specific on RMM 
implementation to provide structure to the meeting 
agenda. However, discussing one issue sparked further 
ideas from stakeholders, and it was the spirit of the ded-
icated meeting to not interrupt such flows of thought. 
Furthermore, specific implementation-relevant aspects 
sometimes matched more than one question. This indi-
cates that the PRAC questions were still rather broad in 
comparison to the specificity of themes critical to imple-
mentation.
3.1.4  Analysis of the Input by Engagement Mechanisms
• The dedicated meeting was deliberately held after the 
public hearing to allow more detailed discussions. When 
comparing these two engagement mechanisms, input was 
overall similar in terms of the breadth of items and their 
content.
• The public hearing yielded more (in the qualitative 
sense) input on: benefit deprivation due to RMM (theme 
2.1); prior knowledge, attitudes, and practice of HCPs 
and patients (themes 3.1 and 3.2); HCP tool preferences 
(theme 3.5); delivery of RMM to HCPs (theme 5.1); and 
immediate implementation (theme 6.1). At the end of 
the public hearing, there was time left to speak for both 
speakers and participants who had attended the hearing 
but had not been a speaker. Their remarks re-enforced or 
expressed agreement with previous statements and did 
not contain new content.
• The dedicated meeting yielded more (in the qualitative 
sense) input on: patient tool preferences (theme 3.6); 
patient burden of RMM (theme 4.3); barriers to RMM 
implementation due to reimbursement issues (theme 4.4); 
and RMM effectiveness measurement (theme 5.3).
• These differences between the public hearing and the 
dedicated meeting may reflect the differences in the ques-
tions posed.
3.2  Proposals for Enhancing Patient and Healthcare 
Professional Engagement for Effective Risk 
Minimisation
From the key findings, three proposals were drawn for 
enhancing the PRAC process of engagement with patients 
and HCPs in relation to RMM and will be presented to 
PRAC, to be considered for piloting in 2021.
3.2.1  Proposal A—Agreement on Risk Minimisation 
Measures
3.2.1.1 Content Analysis Finding The content analysis 
identified shortcomings in convergence among HCPs on 
which RMM are appropriate, i.e. capable to reduce harm 
Table 4  (continued)
Domain Theme code Summary content analysis results and input gaps
6 Time-bound require-
ments of RMM
6.1 Immediate effect Similar input from HCPR and PTR at PH and DM, in response to the PRAC ques-
tion of how to ensure that information is provided to patients at a suitable time, 
stated that RMM needs to be implemented and information provided to patients 
urgently
Input gaps: Healthcare process and leadership for immediate outreach to patients
6.2 Sustainable effect Similar input from HCPR and PTR at PH and DM, in response to the PRAC 
question how to measure risk awareness, stated that information to HCPs and 
patients requires regular updating
Input gaps: Healthcare processes and leadership for maintenance of RMM imple-
mentation
BR benefit-risk balance, DM dedicated stakeholder meeting, GP general practitioner, HCP healthcare professional, HCPR HCP 
representative(s), incl. including, KAP: knowledge, attitudes, practices, MAH marketing authorisation holder, MS member state(s) of the EU, PH 
public hearing, PTR patient representative(s), PPP pregnancy prevention programme, PRAC Pharmacovigilance Risk Assessment Committee, 
RMM risk minimisation measure(s)
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when fully implemented and ethically acceptable, as well as 
on some other themes of RMM implementation.
3.2.1.2 Proposal: Agreeing on Appropriate Risk Minimisa‑
tion Measures with  Stakeholders and  Catalysing Health‑
care Leadership for  Implementation While discussing 
divergent views on RMM is vital and valuable, the lack 
of achieving convergence is detrimental, given that imple-
mentation science has identified agreement between stake-
holders as a key success factor for health interventions [29, 
30]. The responsibility for agreeing and deciding on RMM 
as part of the marketing authorisation lies with the regula-
tory body. Actions A.1, 2 and 3 are proposed to PRAC for 
achieving agreement across stakeholders on which RMM 
are appropriate prior to regulatory decision making and 
catalysing leadership of HCPs for RMM implementation 
in healthcare. For a start, this might improve dissemina-
tion in terms of consistent and synchronised messages on 
new RMM from both regulators and HCPs, which would 
correspond to a need expressed by patients. Further, clini-
cal guidelines might be updated more quickly, and risk 
communication protocols and training could be introduced 
for strengthening skills and confidence of HCPs to tackle 
sensitive communication with patients, corresponding to 
a need expressed by HCPs. Ultimately, full integration 
of RMM in healthcare processes is necessary for RMM 
effectiveness. It must be recognised that agreement of all 
stakeholders may not always be possible, owing to uncer-
tainties about the given risks or RMM implementation, 
persisting divergency among stakeholders, or differences 
in healthcare systems and situations between EU member 
states. Therefore, transparency towards stakeholders and 
the public about the agreements reached, but also about 
dilemmas and causes of divergence might increase the 
understanding of stakeholders for PRAC decisions and 
increase the readiness for implementation, even if a stake-
holder does not fully agree.
• Pilot action A.1: Conduct meetings with stakeholders 
that facilitate creation of common ground, shared prob-
lem ownership, and exchange of expertise and result in 
stakeholder agreement on appropriate RMM
• Pilot action A.2: Motivate leadership in HCP organi-
sations and obtain their commitment for taking respon-
sibilities for immediate and sustainable RMM imple-
mentation in healthcare, including updates of clinical 
guidelines and HCP training
• Pilot action A.3: Increase transparency on agreements 
reached with stakeholders or dilemmas faced by PRAC 
as part of already published rationales of PRAC deci-
sions on RMM
3.2.2  Proposal B—Build‑up Towards Implementable Risk 
Minimisation Measures
3.2.2.1 Content Analysis Finding The content analysis dem-
onstrated that although the PRAC questions at the dedicated 
meeting addressed RMM implementation, stakeholder input 
left gaps regarding some implementation-relevant themes 
and how to overcome barriers  to implementation. Further, 
responses relating to certain RMM implementation themes 
were spread over different questions. Hence, the discussion 
seemed not to have been focused and covered the complete 
implementation process from the regulatory beginning to 
the end in healthcare.
3.2.2.2 Proposal: Building‑up Stakeholder Input 
with  a  Structured Focus on  all Elements Critical to  Risk 
Minimisation Measures Implementation Build-up of com-
prehensive stakeholder input on all elements critical to 
implementation of RMM is proposed for decision making 
and design of RMM. Actions B.1, 2 and 3 include using 
and refining the ASSET for the new purpose of soliciting 
input on the implementability of RMM comprehensively at 
dedicated meetings. This proposal complements the EMA’s 
lesson learnt [37] to keep questions simple, focused and lim-
ited in number at public hearings.
• Pilot action B.1: Use ASSET as a checklist for PRAC 
questions and as a discussion guide for chairpersons of 
dedicated meetings, to ensure soliciting stakeholder input 
on all elements critical to RMM implementation
• Pilot action B.2: Identify through stakeholder discus-
sions barriers and enablers of successful RMM imple-
mentation in healthcare
• Pilot action B.3: Focus discussion outcomes on proac-
tive solutions to overcome foreseeable barriers, inte-
grate RMM in existing healthcare processes and allo-
cate responsibilities for delivery of RMM to HCPs and 
patients
3.2.3  Proposal C—Collaborative Risk Minimisation 
Measures Evaluation
3.2.3.1 Content Analysis Finding Patient and HCP repre-
sentatives described a lack of implementation of the 2014 
RMM and called for an effectiveness evaluation of future 
RMM. The content analysis also identified a lack of exist-
ing research and evidence on the predictable effectiveness in 
terms of RMM objectives as well as some doubts of stake-
holders over the validity of current methods for effective-
ness research, in particular surveys.
Implementation-Based Stakeholder Engagement in Risk Minimisation
3.2.3.2 Proposal: Collaborating with  all Stakeholders 
for  Monitoring of  Implementation and  Evaluation of  Risk 
Minimisation Measures Effectiveness Actions C.1, 2 and 3 
are proposed to strengthen implementation monitoring and 
high-quality RMM effectiveness research in collaboration 
with all stakeholders. In addition to EMA monitoring of 
MAH compliance with RMM requirements and results from 
RMM effectiveness studies imposed on MAHs, real-time 
feedback on receipt of RMM and further implementation 
could be obtained from patients and HCPs. For this pur-
pose, PRAC could intensify their ongoing engagement with 
patient and HCP members of PRAC, the EMA Patients’ 
and Consumers’ Working Party, the EMA Healthcare Pro-
fessionals’ Working Party and the wider EMA stakeholder 
network. Furthermore, studies undertaken by the EMA or 
academia to investigate intended and unintended RMM out-
comes could be planned in collaboration with patient and 
HCP organisations. More active roles of patients and HCPs 
in research, such as defining research topics or collecting 
data, may be developed by applying participatory research 
approaches proven beneficial in other areas such as health 
development [38, 39]. For example, research is needed on 
the effectiveness of pictograms, as patient representatives 
called for this at the public hearing, but preliminary evi-
dence has raised doubts over potential risks of misinterpre-
tation of teratogenicity pictograms. The quality of RMM 
effectiveness studies will be supported with EU good phar-
macovigilance practices currently under revision by PRAC. 
A standard to ensure high-quality reporting of such studies, 
the RIMES statement, has already become available [40] 
and its use will be encouraged in the revised EU good phar-
macovigilance practices.
• Pilot action C.1: Agree with MAH timetables for their 
RMM delivery to patients and HCPs and RMM effective-
ness studies, and publish timetables and updates from 
compliance monitoring on the EMA website
• Pilot action C.2: Investigate together with patient and 
HCP representatives whether and how RMM has reached 
them and been implemented in healthcare by means of a 
methodologically sound survey, focus group, interview 
and pharmacoepidemiological studies
• Pilot action C.3: Promote conduct and high-quality 
research into RMM effectiveness through calls for 
research and methods development
4  Discussion
4.1  Novel Tool ‘ASSET’
The 2017–18 EU procedure for valproate was triggered by 
concerns about insufficient implementation of the 2014 
RMM, and therefore the ASSET for analysing stakeholder 
input was developed based on implementation theories and 
pharmacovigilance experience. It successfully structured 
stakeholder input to the public hearing and dedicated meet-
ing, identified input gaps and allowed comparisons. The 
ASSET might have utility for supporting regulatory deci-
sion making on implementable RMM (see below). Further, 
the ASSET is suggested for piloting with a new purpose, i.e. 
as a checklist and discussion guide for ensuring stakeholder 
input on all elements of implementation. Future application 
may lead to revisions of the tool, allowing wider use for dif-
ferent products, safety concerns, jurisdictions and purposes.
4.2  Limitations of the Content Analysis
Only RMM-related stakeholder input was analysed, not other 
statements such as those on the teratogenic risk itself or the 
lives of affected children and mothers, and not questions on 
accountability. This was in line with the study objectives. 
However, a content analysis of the other input could clarify 
stakeholder expectations towards governments and inform 
initiatives for meeting these expectations.
Regarding the analysed input, it cannot be excluded that 
the real divergence among stakeholders was larger than 
that found in the analysis. This is because only explicitly 
voiced or otherwise obvious (e.g. due to other statements) 
disagreement was recorded; and where no explicit disagree-
ment was voiced, this was interpreted as convergence. Fur-
thermore, body language, which may express agreement or 
disagreement with the statements of others, was not part of 
the analysis.
4.3  Validity of the Content Analysis
A content analysis needs to be valid to serve as evidence for 
policy changes. Validity means that study results truthfully 
reflect the phenomena studied [41] and is mainly achieved 
through the reliability of the analytical methods. This refers 
to how well the analytical method accounts for the informa-
tion inherent in the data and how sensitive it is to distinctions 
in the data for correctly representing the meanings of the 
content [42]. For theory-based studies, reliability is estab-
lished through a coding scheme adherent to its underlying 
theory and through adherence of the analysis to the coding 
rules [43]. In this case study, the ASSET adhered to imple-
mentation theories (see Table 2 of Appendix 2 of the ESM). 
During its development, the draft tool was consulted with 
two co-authors and reviewed by another co-author because 
peer examination of research design is a further means to 
ensure the truth value of qualitative research [44]. The draft 
tool was then tested, which helped finalise the coding rules 
through clarifying the precise scope of each theme. Specific 
attention was paid to adhering to these scopes during the 
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case study. Hence, a range of actions was taken to ensure 
valid results.
4.4  Utility of the Content Analysis for the 2017–18 
European Union Procedure on Valproate 
Teratogenicity and Predictive Value in Relation 
to Ethical Aspects
The content analysis of the stakeholder input was started 
while the 2017–18 EU procedure for valproate was ongo-
ing, and its preliminary results were shared with PRAC 
in January 2018 prior to their decision making. The pre-
liminary results predicted that ethical aspects (theme 1.2) 
would become highly relevant for the final discussions and 
decision making on a PPP: there was overall stakeholder 
convergence on risk and family planning counselling to 
support informed choice for women. HCP representatives 
raised questions about how to act if a woman without an 
alternative to valproate is or plans to become pregnant, or 
does not need contraception because a pregnancy is excluded 
otherwise, or if there are doubts over adherence to a PPP. 
Most HCP representatives felt that these women, and their 
unborn children, cannot be deprived from life-saving treat-
ment because of regulatory requirements and that they need 
to be supported by the healthcare system regardless of their 
choices. These HCP representatives experienced a dilemma 
between the medical needs of their patients and wanting to 
adhere to safe use requirements and regulation. These pre-
liminary results from the content analysis, in addition to the 
regular records of the stakeholder input (see Sect. 2.2), were 
appreciated by the PRAC rapporteurs, as the stakeholder 
feedback was very extensive and listening by any individual 
can naturally be selective. They stated that the preliminary 
results reassured them in their overall understanding of the 
stakeholders’ views and offered an additional perspective 
on the stakeholder input that broadened their awareness of 
potential issues.
4.5  Added Value of a Public Hearing for Regulatory 
Decision Making
The public hearing provided PRAC with multi-perspective 
insights into problems with real-world healthcare. This was 
instrumental for PRAC deciding on new RMM, including 
a new PPP and a visual warning on the teratogenic risk on 
the outer packaging. A survey and a lessons learnt analy-
sis conducted by EMA reported that the majority of PRAC 
members said that “they learnt something new” and 79% 
specifically said that it would “make a difference to the 
assessment of valproate”. Overall, EMA concluded that the 
hearing improved the quality of the assessment [37]. In par-
ticular, the PRAC rapporteurs were able to confirm that the 
2014 RMM were considered by patients as an “excellent 
toolkit”, but that more needed to be done for the delivery of 
RMM to patients and HCPs.
4.6  Added Value of a Public Hearing for the Texture 
of Engagement
Different from written consultations, face-to-face inter-
actions provide a higher degree of what has been named 
‘texture’ in a conceptualisation of pharmacovigilance 
engagement developed for the PRAC Impact Strategy. 
There, texture describes “the interactive dynamics of what 
engagement feels like, what it means to people, and how 
this shapes motivations to engage and change behaviour—
based on values, emotions, (mis)trust and rationales” [45]. 
The EMA survey after the public hearing demonstrated the 
added value of the hearing in terms of texture. One hun-
dred percent of the stakeholder respondents felt that the 
hearing was a “positive experience” and 88% felt that it 
“would make a difference to the Committee recommen-
dations” [37]. An individual patient representative sees in 
public hearings a major sign of regulatory commitment and 
trustworthiness and describes them as a chance for patients 
to make impactful presentations that have visibility to the 
world (François Houÿez, European Organisation for Rare 
Diseases [EURORDIS], personal communication, 3 March, 
2020). As public hearings are broadcast live by the EMA 
and the recording remains available on the EMA website, 
the EMA provides transparency of the texture of the inter-
actions, beyond publishing the written submissions to the 
public hearing.
Although the case study was not a discourse analysis on 
the use of language nor a sentiment analysis, the following 
reflections are offered here regarding the texture of the pub-
lic hearing on the basis of the content analysis and related 
observations. The face-to-face interaction allowed for the 
expression of mutual thanks for the invitations and the input 
in a personal manner. The chairperson could create a com-
mon ground among all stakeholders at the beginning of the 
hearing by highlighting its significance and objectives. Some 
patient representatives shared personal experiences of the 
medical, practical, and emotional impact of the valproate 
teratogenicity for the affected children and families. Fur-
thermore, individual or others’ complaints were conveyed 
about not having received the 2014 RMM and delays in risk 
identification and warnings; questions were raised regarding 
trustworthiness, responsibilities and MAHs’ accountabil-
ity; references were made to interactions with parliaments 
and political contexts; and clear demands were directed at 
the authorities. Patient representatives brought samples of 
valproate tablets dispensed in plastic bags without package 
leaflets or in blister packages without the name of the active 
substance printed on the blister, and also samples of patient 
cards, which they described as “small and flimsy”. Seeing 
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such physical samples might have been more impactful than 
photos. Moreover, there was the opportunity for PRAC to 
ask for details and confirm understanding with the speakers 
directly. Some speakers chose to present in their own lan-
guage if this was not English and have their input translated 
by a trusted person into English as the working language 
of the hearing. Regulators verbally expressed empathy and 
appreciation of the time taken, the altruism and the cour-
age of those affected to share personal experiences in the 
public domain. They also acknowledged the seriousness of 
the problem to solve and confirmed to apply the regulatory 
tools in the best way possible “to get this right”. Although 
body language was not part of the analysis, postures, facial 
expressions, and tone of voice of regulators corresponding 
to attention, seriousness, and empathy were observed by the 
authors and have probably contributed to the engaging tex-
ture of the interaction. Likewise, there was verbal and bodily 
expression of sympathy and commitment to change from 
some HCP representatives vis-à-vis the patients.
4.7  Broad Scope of Risk Minimisation in Healthcare
The content analysis highlighted that stakeholders con-
tributed experiences, expectations and suggestions for risk 
minimisation beyond the remit of regulatory bodies. These 
related to healthcare, such as family planning counselling, 
healthcare software and nationwide risk awareness cam-
paigns. Hence, a view on risk minimisation broader than 
what can be demanded through regulatory action had to be 
applied in this case study, and the term RMM had to be used 
with this broader understanding beyond its regulatory defi-
nition. Even for RMM in the regulatory sense, their imple-
mentation requires dissemination and changes in knowledge, 
attitude and practice in healthcare, which are not subject to 
the regulation of medicines. It is unlikely that patients and 
HCPs can have the in-depth knowledge of medicine regula-
tion for differentiating between the respective remits of regu-
latory bodies and healthcare supervision. Most importantly, 
the interactions between patients, HCPs and regulators are 
meant to be an open dialogue about RMM and their imple-
mentation in the context of other measures for patient care. 
This broader insight may allow regulators to design RMM 
that are implementable in real-world healthcare.
5  Conclusions
Enhancing engagement between regulators, patients and HCPs 
is considered one of the most important areas of progress for 
ensuring a positive impact of pharmacovigilance [46]. This 
case study analysed the stakeholder input at the first ever 
EMA public hearing and subsequent dedicated meeting. For 
this analysis, the novel ASSET was developed on the basis 
of implementation theories and could be used for further 
purposes. The analysis identified several important gaps in 
stakeholder input and research relating to critical elements of 
RMM implementation. From the results, three proposals with 
practical actions were derived to be considered by PRAC for 
piloting, to establish how these actions can most efficiently 
(i.e. in a prioritised risk-proportionate manner) contribute 
to improving regulatory stakeholder engagement and RMM 
decision making. Among the three proposals, achieving stake-
holder agreement on RMM and catalysing healthcare leader-
ship for RMM implementation may be the most challenging 
for regulators because this concerns connecting more with 
patients and HCPs, their real-world experiences and potential 
for behavioural change within healthcare systems. Inspired 
by one of the widely acclaimed principles for being effective 
in life, “Begin with the end in mind” [47], the approach of 
applying implementation theories to RMM may be coined as 
‘Begin with the implementation-end in mind’. This is expected 
to enhance mutual engagement, trust building and respective 
leadership of all stakeholders through jointly envisioning the 
intended positive RMM outcomes upfront, and then design-
ing together RMM that can change medicine use for patient 
safety and health.
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